Symbol not found

NASDAQ:IBRX   00:00AM GMT
0.00
0.00 (0.00%)
Products

Immunitybio Says FDA Accepts BLA For Bladder Cancer Carcinoma Treatment

Published: 07/28/2022 22:16 GMT
ImmunityBio Inc (IBRX) - Immunitybio Announces FDA Acceptance of Biologics License Application for N-803 in Bcg-unresponsive Non-muscle-invasive Bladder Cancer Carcinoma in Situ.
Immunitybio Inc - Target PDUFA Date is May 23, 2023.